MG
IMNM icon

Michael Gelband’s Immunome IMNM Stock Holding History

Michael Gelband’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-115,370
Closed -$2.52M – 1801
2026
Q1 		$2.52M Sell
115,370
-664,208
-85% -$14.8M 0.02% 683
2025
Q4 		$16.7M Buy
+779,578
New +$13.7M 0.13% 132
2025
Q3 		– Sell
-81,873
Closed -$761K – 1761
2025
Q2 		$761K Sell
81,873
-20,280
-20% -$166K 0.01% 1042
2025
Q1 		$687K Buy
+102,153
New +$980K 0.01% 1024
2024
Q2 		– Sell
-34,991
Closed -$864K – 1726
2024
Q1 		$864K Buy
34,991
+1,849
+6% +$37.5K 0.01% 994
2023
Q4 		$355K Buy
+33,142
New +$276K ﹤0.01% 1128
2021
Q3 		– Sell
-12,800
Closed -$221K – 2360
2021
Q2 		$221K Buy
+12,800
New +$283K ﹤0.01% 1918

Other funds holding IMNM

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

Michael Gelband's IMNM Position: Q2 2026 in Review

Michael Gelband sold out of Immunome (IMNM) in Q2 2026, closing a stake of 115,370 shares — an estimated $2.52M sold.

Michael Gelband first reported a position in IMNM in Q2 2021 and held it in 7 quarters. The position peaked at $16.7M in Q4 2025. 200 funds tracked by Wall St. Rank hold IMNM as of Q2 2026.

  • Michael Gelband reported no remaining Immunome position as of Q2 2026 after selling out during the quarter.
  • Michael Gelband sold 115,370 Immunome shares in Q2 2026, an estimated $2.52M.
  • Michael Gelband first reported a position in Immunome in Q2 2021 and held it in 7 quarters.
  • Michael Gelband's Immunome position peaked at $16.7M in Q4 2025.
  • 200 funds tracked by Wall St. Rank held Immunome as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.